Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,150 GBX | +2.29% | +3.24% | +22.26% |
Mar. 26 | Dr Martens cut to 'sell'; BofA likes Tullow | AN |
Mar. 25 | Judges Scientific Chair Hambro sells GBP110,000 in shares | AN |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 351.7 | 401.9 | 530.7 | 537.6 | 603.4 | 740.3 | - | - |
Enterprise Value (EV) 1 | 352 | 407.6 | 529.3 | 576.7 | 648.1 | 769.8 | 753.2 | 740.9 |
P/E ratio | - | - | - | - | 63.6 x | 46.6 x | 40.9 x | 37.3 x |
Yield | 0.88% | 0.86% | 0.79% | 0.96% | 1.04% | 0.93% | 1.02% | 1.11% |
Capitalization / Revenue | 4.26 x | 5.03 x | 5.81 x | 4.75 x | 4.43 x | 5.23 x | 4.95 x | 4.73 x |
EV / Revenue | 4.27 x | 5.1 x | 5.8 x | 5.09 x | 4.76 x | 5.44 x | 5.04 x | 4.73 x |
EV / EBITDA | 18.5 x | 25.1 x | 25.3 x | 17.7 x | 17.1 x | 19 x | 17.5 x | 16.4 x |
EV / FCF | 24.5 x | 41.3 x | 40.3 x | 47.1 x | 29.7 x | 35.4 x | 30.5 x | 26.4 x |
FCF Yield | 4.08% | 2.42% | 2.48% | 2.12% | 3.36% | 2.83% | 3.28% | 3.79% |
Price to Book | - | - | - | - | 7.32 x | 7.12 x | 5.91 x | 5 x |
Nbr of stocks (in thousands) | 6,224 | 6,299 | 6,318 | 6,370 | 6,616 | 6,640 | - | - |
Reference price 2 | 56.50 | 63.80 | 84.00 | 84.40 | 91.20 | 111.5 | 111.5 | 111.5 |
Announcement Date | 3/18/20 | 3/22/21 | 3/23/22 | 3/22/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 82.5 | 79.86 | 91.29 | 113.2 | 136.1 | 141.4 | 149.5 | 156.6 |
EBITDA 1 | 19.02 | 16.22 | 20.88 | 32.55 | 38 | 40.6 | 42.92 | 45.15 |
EBIT 1 | 17.38 | 14.36 | 18.78 | 30.11 | 34.8 | 36.76 | 38.67 | 40.94 |
Operating Margin | 21.07% | 17.98% | 20.57% | 26.6% | 25.57% | 25.99% | 25.86% | 26.14% |
Earnings before Tax (EBT) 1 | 13.63 | 9.473 | 14.86 | 15.97 | 13.4 | 27.33 | 30.27 | 33.17 |
Net income 1 | 11.85 | 8.22 | 11.69 | 12.78 | 9.9 | 21.83 | 23.9 | 25.93 |
Net margin | 14.37% | 10.29% | 12.8% | 11.28% | 7.27% | 15.44% | 15.98% | 16.56% |
EPS 2 | - | - | - | - | 1.435 | 2.394 | 2.729 | 2.991 |
Free Cash Flow 1 | 14.37 | 9.871 | 13.14 | 12.24 | 21.8 | 21.75 | 24.72 | 28.11 |
FCF margin | 17.42% | 12.36% | 14.39% | 10.82% | 16.02% | 15.38% | 16.53% | 17.95% |
FCF Conversion (EBITDA) | 75.57% | 60.86% | 62.92% | 37.62% | 57.37% | 53.58% | 57.59% | 62.26% |
FCF Conversion (Net income) | 121.24% | 120.09% | 112.41% | 95.85% | 220.2% | 99.63% | 103.43% | 108.39% |
Dividend per Share 2 | 0.5000 | 0.5500 | 0.6600 | 0.8100 | 0.9500 | 1.037 | 1.140 | 1.234 |
Announcement Date | 3/18/20 | 3/22/21 | 3/23/22 | 3/22/23 | 3/21/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | 0.33 | 5.7 | - | 39.1 | 44.7 | 29.4 | 12.8 | 0.58 |
Net Cash position 1 | - | - | 1.4 | - | - | - | - | - |
Leverage (Debt/EBITDA) | 0.0172 x | 0.3515 x | - | 1.202 x | 1.176 x | 0.7251 x | 0.2992 x | 0.0127 x |
Free Cash Flow 1 | 14.4 | 9.87 | 13.1 | 12.2 | 21.8 | 21.8 | 24.7 | 28.1 |
ROE (net income / shareholders' equity) | - | - | - | - | 35.7% | 25.1% | 22.4% | 20.5% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | 12.50 | 15.70 | 18.90 | 22.30 |
Cash Flow per Share 2 | - | - | - | - | 4.000 | 5.120 | 5.330 | 5.640 |
Capex 1 | 1.3 | 1.25 | 2.58 | 6.36 | 4.7 | 5.37 | 5.6 | 2.1 |
Capex / Sales | 1.58% | 1.57% | 2.82% | 5.61% | 3.45% | 3.79% | 3.75% | 1.34% |
Announcement Date | 3/18/20 | 3/22/21 | 3/23/22 | 3/22/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.26% | 922M | |
+11.73% | 82.35B | |
+20.17% | 71.09B | |
+20.89% | 37.72B | |
+15.77% | 32.01B | |
+9.19% | 27.2B | |
+3.18% | 26.74B | |
+4.22% | 26B | |
+16.93% | 25.5B | |
+17.14% | 24.76B |
- Stock Market
- Equities
- JDG Stock
- Financials Judges Scientific plc